Morbidity, Mortality, and Care Gaps: Gout is bidirectionally associated with CKD, hypertension, type 2 diabetes, metabolic syndrome, and increased all-cause and cardiovascular mortality. Despite being a curable crystal deposition disease, a major population-level care gap persists: national epidemiological data show that only ~33% to 35.5% of U.S. patients with gout receive urate-lowering therapy (ULT), leading to avoidable joint destruction, tophi, and recurrent acute care utilization.